AzacitidineAntimetabolites, AntineoplasticMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicChromatography, Supercritical FluidCompassionate Use TrialsInjections, SubcutaneousLeukemia, Myeloid, AcuteTreatment OutcomeAnemia, RefractoryConsolidation ChemotherapyInduction ChemotherapyAnemia, Refractory, with Excess of BlastsDrug ApprovalDNA MethylationDrug Administration ScheduleDNA Modification MethylasesSurvivalInternational AgenciesEpigenomicsUnited States Food and Drug AdministrationThalidomideRemission InductionAntineoplastic Combined Chemotherapy ProtocolsBiological AvailabilityAntimetabolitesBlood TransfusionCytarabineTetrazolium SaltsLeukemia, MyeloidMaximum Tolerated DoseRetrospective StudiesRandomized Controlled Trials as TopicRecurrenceAcute DiseaseFatigueSurvival AnalysisInfusions, IntravenousHematopoietic Stem Cell TransplantationEnzyme InhibitorsCell Line, TumorTransplantation, HomologousDisease Progression